Sign In
Buy NDAQ
$82.49
-0.120 (-0.145%)
At Close: Jun 23, 2026
QTOP: Risky Play On Nasdaq-100 Top 30 Stocks, But Worth A Look
06:40am, Tuesday, 06'th May 2025
iShares Nasdaq Top 30 Stocks ETF offers exposure to top Nasdaq stocks with lower concentration risk compared to TOPT, but has underperformed recently due to high valuations. QTOP's performance hinges
Nasdaq 100: AMD Earnings in Focus as Data Center Growth Faces Tariff Headwinds
05:42am, Tuesday, 06'th May 2025
AMD Q1 earnings preview: Strong data center growth expected, but China tariffs and gaming weakness may weigh on guidance. Here's what traders need to know.
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 05'th May 2025
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on May 1, 2025, the Compensation Committee of the company's Board of Directors granted to 13
Nasdaq Reports April 2025 Volumes
04:05pm, Monday, 05'th May 2025
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today reported monthly volumes for April 2025 on its Investor Relations website. A data sheet showing this information can be found at:
Nasdaq Falls Over 100 Points; Tyson Foods Posts Downbeat Sales
09:54am, Monday, 05'th May 2025
U.S. stocks traded lower this morning, with the Nasdaq Composite falling more than 100 points on Monday.
Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025
07:30am, Monday, 05'th May 2025
WAYNE, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercia
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Friday, 02'nd May 2025
BOSTON, May 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:42pm, Friday, 02'nd May 2025
VANCOUVER, British Columbia and BOSTON, May 02, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developin
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 02'nd May 2025
SAN FRANCISCO, May 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, de
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 02'nd May 2025
WALTHAM, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:10pm, Friday, 02'nd May 2025
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options
Bon Natural Life Limited Announces Receipt of Nasdaq Delisting Notifications
04:10pm, Friday, 02'nd May 2025
XI'AN, China, May 02, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) (“BON” or the “Company”), one of the leading bio-ingredient solutions providers in the natural, health and
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 02'nd May 2025
BOSTON , May 02, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on April 30, 2025, t
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 02'nd May 2025
REDWOOD CITY, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement a
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 02'nd May 2025
NAARDEN, the Netherlands and MIAMI, May 02, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutica
